Pyrazinoic acid (POA) is a pyrazinamide (PZA) metabolite. Mycobacterium tuberculosis pyrazinamidase converts pyrazinamide into this compound, the active form of pyrazinamide. The cognate anion is called pyrazinoate. It inhibits panD, the aspartate 1-decarboxylase. It also inhibits Rv2783 (gpsI), a polyribonucleotide nucleotidyltransferase and guanosine pentaphosphate synthetase.
Role in tuberculosis treatment One way M. tuberculosis becomes resistant to PZA is by disabling the pyrazinamidase by through mutations. Using another chemical precursor to POA could bypass this problem. (POA cannot be directly used because it is not lipophilic enough to cross the bacterial cell membrane at physiological pH, being mostly ionized.) One group of proposed alternative prodrugs is the esters of POA (pyrazinoate esters). It has been shown in vitro that their MICs are lower than PZA, meaning they are more potent antibiotics. Moreover, they cross the bacterial membrane more easily, due to their higher lipophilicity.
References



